BRPI0919245A2 - Vacina para malária - Google Patents

Vacina para malária

Info

Publication number
BRPI0919245A2
BRPI0919245A2 BRPI0919245A BRPI0919245A BRPI0919245A2 BR PI0919245 A2 BRPI0919245 A2 BR PI0919245A2 BR PI0919245 A BRPI0919245 A BR PI0919245A BR PI0919245 A BRPI0919245 A BR PI0919245A BR PI0919245 A2 BRPI0919245 A2 BR PI0919245A2
Authority
BR
Brazil
Prior art keywords
malaria
fertilization
immunogenic compositions
malaria vaccine
vaccine
Prior art date
Application number
BRPI0919245A
Other languages
English (en)
Inventor
Evelina Angov
Nirbhay Kumar
Original Assignee
Us Gov Sec Army
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Sec Army, Univ Johns Hopkins filed Critical Us Gov Sec Army
Publication of BRPI0919245A2 publication Critical patent/BRPI0919245A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

vacina para malária. a presente invenção refere-se a composições imunogênicas baseadas nos antígenos de pré-fertilização ou de pós-fertilização expressos nos gametócitos circulantes no sangue periférico de pessoas infectadas ou nos estágios de desenvolvimento de parasitas da malária no intestino inter mediário do mosquito incluindo gametas do sexo masculino e do sexo feminino extracelulares, zigoto fertilizado e oocineto. a invenção apresenta ainda processos para a prevenção da transmissão de malária utilizando as compo- sições imunogênicas da invenção.
BRPI0919245A 2008-09-24 2009-07-22 Vacina para malária BRPI0919245A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9965108P 2008-09-24 2008-09-24
PCT/US2009/004243 WO2010036293A1 (en) 2008-09-24 2009-07-22 Malaria vaccine

Publications (1)

Publication Number Publication Date
BRPI0919245A2 true BRPI0919245A2 (pt) 2021-11-03

Family

ID=42060015

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919245A BRPI0919245A2 (pt) 2008-09-24 2009-07-22 Vacina para malária

Country Status (5)

Country Link
US (1) US8501926B2 (pt)
EP (1) EP2331119A4 (pt)
AU (1) AU2009297127A1 (pt)
BR (1) BRPI0919245A2 (pt)
WO (1) WO2010036293A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220072115A1 (en) * 2018-11-07 2022-03-10 Rhode Island Hospital Malaria antigens on the surface of erythrocytes and merozoites and protective antibodies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333406B1 (en) * 1988-08-12 2001-12-25 Joseph W. Inselburg Gene encoding protein antigens of Plasmodium falciparum and uses therefor
US5798106A (en) * 1990-06-06 1998-08-25 University Of Nijmegan Protein
AU1588092A (en) * 1991-02-22 1992-09-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Transmission blocking vaccine against malaria
US5502168A (en) * 1991-10-24 1996-03-26 The Johns Hopkins University Monoclonal antibodies to a continuous and cross-reactive epitope and an isolated protein of a sexual stage of P. falciparum
US5527700A (en) * 1992-07-10 1996-06-18 The United States Of America As Represented By The Department Of Health And Human Services Target antigens of transmission blocking antibodies for malaria parasites
NL9202026A (nl) * 1992-11-20 1994-06-16 Stichting Katholieke Univ Recombinant nuclëinezuur, daardoor gecodeerd polypeptide materiaal en daarop gebaseerd transmissie-blokkerend vaccin ter bestrijding van de malariaparasiet Plasmodium falciparum.
WO1994017187A1 (en) * 1993-01-29 1994-08-04 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services CLONING AND EXPRESSION OF PLASMODIUM FALCIPARUM TRANSMISSION-BLOCKING TARGET ANTIGEN, Pfs230
FR2744724B1 (fr) * 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
DE19640817A1 (de) * 1996-10-02 1998-05-14 Hermann Prof Dr Bujard Rekombinantes Herstellungsverfahren für ein vollständiges Malaria-Antigen gp190/MSP 1
US7407658B2 (en) * 1997-05-01 2008-08-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vaccines for blocking transmission of plasmodium vivax
US7192934B1 (en) * 1997-05-01 2007-03-20 The United States Of America As Represented By The Department Of Health And Human Services Vaccines for blocking transmission of Plasmodium vivax
US20050096288A1 (en) * 1997-06-13 2005-05-05 Aragene, Inc. Lipoproteins as nucleic acid vectors
US6846481B1 (en) * 1999-02-04 2005-01-25 University Of Georgia Research Foundation, Inc. Recombinant expression of heterologous nucleic acids in protozoa
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
WO2002059319A1 (fr) * 2001-01-24 2002-08-01 The Research Foundation For Microbial Diseases Of Osaka University Polypeptide se36 de l'antigene malaria plasmodium, procede de purification dudit polypeptide, vaccin et methode diagnostique utilisant l'antigene ainsi obtenu
AU2002336760A1 (en) * 2001-09-26 2003-06-10 Mayo Foundation For Medical Education And Research Mutable vaccines
EP1490494A1 (en) 2002-04-01 2004-12-29 Walter Reed Army Institute of Research Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
DK1511768T3 (da) * 2002-06-11 2007-08-20 Glaxosmithkline Biolog Sa Immunogene sammensætninger
US7550275B2 (en) * 2002-11-12 2009-06-23 The United States Of America As Represented By The Secretary Of The Navy Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide
WO2004055187A1 (en) * 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
US7550263B2 (en) * 2003-09-05 2009-06-23 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2006093524A2 (en) * 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates
US20060233789A1 (en) * 2004-09-24 2006-10-19 Cellfree Science Co., Ltd. Process for producing antigenic substance
WO2006124712A2 (en) 2005-05-16 2006-11-23 Merck & Co., Inc. A method for improving the immunogenicity of plasmodium antigens
CN103122360A (zh) * 2006-02-28 2013-05-29 瓦克萨特公司 嵌合腺病毒载体
CA2657353A1 (en) * 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送

Also Published As

Publication number Publication date
EP2331119A4 (en) 2012-05-30
WO2010036293A1 (en) 2010-04-01
US8501926B2 (en) 2013-08-06
WO2010036293A8 (en) 2010-06-03
AU2009297127A1 (en) 2010-04-01
US20110171266A1 (en) 2011-07-14
EP2331119A1 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
MX375202B (es) Composiciones adyuvantes novedosas.
CO6382140A2 (es) Composiciones de vacuna que comprenden una proteina de enlace del factor h mutada
PH12013502621A1 (en) Vaccine composition comprising an inactivated chikungunya virus strain
EA201290956A1 (ru) Вакцина против вич
EA201270063A1 (ru) Рекомбинантные антигены pcb
MX340830B (es) Vacuna neumococica y usos de la misma.
MX341395B (es) Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc.
BR112014006988A2 (pt) sistema de fraturamento ajustável
BR112016015422A2 (pt) formulações de vacina de frasco único
WO2010151076A3 (ko) 폴리감마글루탐산-키토산 나노입자를 함유하는 면역보강제 조성물
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
MX381211B (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
MY158200A (en) Conjugates for the prevention of treatment of nicotine addiction
DK201300292A (en) Fish vaccine
MX342832B (es) Tratamiento o prevencion de una infeccion.
EP2925126A4 (en) PLANT VENDING OF AGRICULTURAL PESTS SUCH AS SNACK PLUMBERS, BUTTERFLIES AND BEETLES
ECSP099066A (es) Vacuna combinada estreptococica
WO2010104281A3 (ko) 아토피성 피부질환 개선용 조성물
CY1116077T1 (el) Τοπικες συνθεσεις για την προληψη σεξουαλικα μεταδιδομενων ασθενειων και μεθοδοι για την παραγωγη αυτων
BR112013023354A2 (pt) vacina para rinite equina
WO2010036293A8 (en) Malaria vaccine
MX2017007856A (es) Composicion para el cuidado bucal.
CA2865777A1 (en) 2,2',6,6'-tetraisopropyl-4,4'-biphenol lipid microsphere preparations and preparation methods therefor
GB201112587D0 (en) Vaccine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2653 DE 09-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.